Acceleration 2011 logo.png

Untitled Document



3:00 – 3:30 p.m.


3:30 – 3:45 p.m.

Welcome & Introduction


Thomas J. Engellenner
Partner, Intellectual Property
Nutter McClennen & Fish LLP


Keynote Speaker


Michelle Dipp, M.D., Ph.D.
Founder and Partner
Longwood Founders Fund

4:00 – 5:15 p.m.

Panel I: How Lean is too Lean?
Balancing capital efficiency with building a successful, scalable business




Michelle L. Basil
Partner, Emerging Companies and Life Sciences Groups
Nutter McClennen & Fish LLP




Bruce L. Booth, D. Phil
Partner, Life Sciences Group
Atlas Venture


Stephen DeMarci
Partner, Health Industries Practice


Bill Gruber
President and Chief Executive Officer
Solace Therapeutics


Laurie Halloran
Chief Executive Officer
Halloran Consulting Group


The need for capital efficiency among emerging life science companies has been widely discussed. This panel will examine the pitfalls and challenges faced by development-stage life science companies as they execute on a lean business model, from raw technology through the clinical and operational phases of development. Panelists will address how to raise an optimum level of capital to grow the right team and build the right clinical trial program for successful commercial launch or acquisition.

5:15 – 5:30 p.m.


5:30 – 5:45 p.m.

Keynote Speaker


Patrice M. Milos, Ph.D.
Site Head
Pfizer, Centers for Therapeutic Innovation, Boston


Panel II: Are Big Pharma and Big Device the New Development Accelerators?
How industry leaders are supporting external innovation to acquire, option, develop and commercialize new products

5:45 – 7:00 p.m.



Maria D. Buckley
Of Counsel, Life Sciences Group
Nutter McClennen & Fish LLP



Brian M. Gallagher, Jr., Ph.D.
SR One Ltd.


Donald D. Haut, Jr., Ph.D.
Senior Vice President for Strategy & Business Development
Advanced Surgical Devices Division, Smith & Nephew


Julius (Jay) Knowles, MS, MBA
Head, Platforms, Strategic Alliances
Novartis Institutes for BioMedical Research


Gregory L. Miller   
Head of Business and Corporate Development
Concert Pharmaceuticals, Inc.


Panelists will examine how large life science companies are deploying new external investment and development models to optimize their “buy” and “build” product pipelines. This panel will discuss innovative business models and partnerships deployed by larger companies to emulate and harness the innovative engines of emerging life science companies to create, develop and commercialize new products in a capital efficient fashion.

7:00 – 8:00 p.m.

Cocktails & Hors d’oeuvres